Target
Interleukin-1 receptor-associated kinase 4
Ligand
BDBM210298
Substrate
n/a
Meas. Tech.
ChEMBL_1991895 (CHEMBL4625630)
IC50
9.3±n/a nM
Citation
 Nair, SKumar, SRPaidi, VRSistla, RKantheti, DPolimera, SRThangavel, SMukherjee, AJDas, MBhide, RSPitts, WJMurugesan, NDudhgoankar, SNagar, JSubramani, SMazumder, DCarman, JAHolloway, DALi, XFereshteh, MPRuepp, SPalanisamy, KMariappan, TTMaddi, SSaxena, AElzinga, PChimalakonda, ARuan, QGhosh, KBose, SSack, JYan, CKiefer, SEXie, DNewitt, JASaravanakumar, SPRampulla, RABarrish, JCCarter, PHHynes, J Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis. ACS Med Chem Lett 11:1402-1409 (2020) [PubMed]  Article
Target
Name:
Interleukin-1 receptor-associated kinase 4
Synonyms:
IRAK-4 | IRAK4 | IRAK4_HUMAN | Interleukin-1 receptor-associated kinase 4 (IRAK-4) | Interleukin-1 receptor-associated kinase 4 (IRAK4) | Renal carcinoma antigen NY-REN-64
Type:
Protein
Mol. Mass.:
51519.08
Organism:
Homo sapiens (Human)
Description:
Q9NWZ3
Residue:
460
Sequence:
MNKPITPSTYVRCLNVGLIRKLSDFIDPQEGWKKLAVAIKKPSGDDRYNQFHIRRFEALLQTGKSPTSELLFDWGTTNCTVGDLVDLLIQNEFFAPASLLLPDAVPKTANTLPSKEAITVQQKQMPFCDKDRTLMTPVQNLEQSYMPPDSSSPENKSLEVSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS
  
Inhibitor
Name:
BDBM210298
Synonyms:
US9546153, ex. 366
Type:
Small organic molecule
Emp. Form.:
C21H24FN5O2S
Mol. Mass.:
429.511
SMILES:
CC(C)(O)[C@@H](F)CNC(=O)c1cnc(Nc2ccc3ncsc3c2)cc1NC1CC1 |r|
Structure:
Search PDB for entries with ligand similarity: